Wire · opportunities
FDA approves life-extending pancreatic cancer drug Rasonque
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The FDA approved Rasonque, a new pancreatic cancer drug by Revolution Medicines, after clinical trials showed it nearly doubles life expectancy for patients with metastatic disease. The drug received expedited FDA review and is now available in the US at $39,800 per month, with assistance for insured patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
The FDA cut approval times drastically for Rasonque, opening a big new market in pancreatic cancer treatment that you can now target with faster market access. Prepare to compete on access and patient affordability given the drug’s expensive price but broad insurance support.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics